about
Towards detecting the HER-2 receptor and metabolic changes induced by HER-2-targeted therapies using medical imaging.Magnetic resonance detects metabolic changes associated with chemotherapy-induced apoptosisSynthesis and characterisation of biologically compatible TiO2 nanoparticles.Response to trastuzumab by HER2 expressing breast tumour xenografts is accompanied by decreased Hexokinase II, glut1 and [18F]-FDG incorporation and changes in 31P-NMR-detectable phosphomonoesters.Influence of resistance to 5-fluorouracil and tomudex on [18F]‑FDG incorporation, glucose transport and hexokinase activity.18F -PEG-biotin: Precursor (boroaryl-PEG-biotin) synthesis, 18F -labelling and an in-vitro assessment of its binding with Neutravidin™-trastuzumab pre-treated cells.Colorectal tumor cells treated with 5-FU, oxaliplatin, irinotecan, and cetuximab exhibit changes in 18F-FDG incorporation corresponding to hexokinase activity and glucose transport.Decreased [18F]fluoro-2-deoxy-d-glucose incorporation and increased glucose transport are associated with resistance to 5FU in MCF7 cells in vitro.Treatment of breast tumor cells in vitro with the mitochondrial membrane potential dissipater valinomycin increases 18F-FDG incorporation.[methyl-3H]Choline incorporation into MCF7 tumour cells: correlation with proliferation.99mTc-labelled human serum transferrin for tumour imaging: an in vitro and in vivo study of the complex.Response Detection of Castrate-Resistant Prostate Cancer to Clinically Utilised and Novel Treatments by Monitoring Phospholipid Metabolism.Proliferation is associated with 2-deoxy-D-[1-3H]glucose uptake by T47D breast tumour and SW480 and SW620 colonic tumour cells.[18F]2-fluoro-2-deoxy-D-glucose incorporation by AGS gastric adenocarcinoma cells in vitro during response to epirubicin, cisplatin and 5-fluorouracil.The labelling of human serum transferrin with 99mTc and a study concerning uptake of the complex by tumour cells.Gut protection by cyclophosphamide "priming" in patients receiving high-dose melphalan--effect of drug scheduling.Combination treatment of cancer cells with pan-Akt and pan-mTOR inhibitors: effects on cell cycle distribution, p-Akt expression level and radiolabelled-choline incorporation.Optimized MR imaging for polyacrylamide gel dosimetryHuman serum transferrin cobalt complex: stability and cellular uptake of cobaltOne-pot production of 18F-biotin by conjugation with 18F-FDG for pre-targeted imaging: synthesis and radio-labelling of a PEGylated precursorCDP-choline accumulation in breast and colorectal cancer cells treated with a GSK-3-targeting inhibitor
P50
Q36324211-1A40D639-F0DD-48B5-8FC0-7C10315A46FFQ36620298-78EDCE97-4BFF-4D7F-B9F3-ED81D288E098Q39001887-CE203707-87DA-48FF-8059-3F966325F02FQ39239280-6D590D0E-8E10-4E5F-BEED-A042E66B6CBDQ39350367-9EA645DB-CAA3-4A48-9640-C9539215C7FCQ39538565-5E466C4F-197B-40AE-86E9-BCA7BC5212EDQ39960608-5E9925DD-E6F7-4DEF-9139-009B9BD973D3Q40053022-1191D61A-F477-4BD7-BE04-93416D101B08Q40098625-5C8B5642-6469-4086-8B00-4B3520F549FCQ40468726-74D4C81D-1A2A-4810-BF78-DAA8150AE85DQ40564656-8A30D027-DA44-4A82-AF4D-484486D13D39Q40955130-266AA623-3EB9-44A8-A02F-F07105DC3E23Q41012584-B1E86F13-EED9-4158-9951-86643C13D7E0Q41987666-B755C20D-6C2C-49ED-A7A4-BBA22F44AC8FQ44201993-D1C68A62-25D4-4F2B-988B-DD49582A1238Q45197905-E55D0332-E01D-4CAA-93ED-38D5EF418403Q64982984-453C557C-3D04-4052-8964-4BF95B8E5A70Q73745397-4A20D383-B156-4093-82D4-06F532443D06Q81798875-B0B0C17C-3D99-4DD7-8D22-1D6D7BF56627Q82413792-F985799A-78CA-4D8C-958B-AEF38558AF05Q93185115-624F4A67-05E8-4F38-ABB9-2A0042505968
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Tim A D Smith
@ast
Tim A D Smith
@en
Tim A D Smith
@es
Tim A D Smith
@nl
Tim A D Smith
@sl
type
label
Tim A D Smith
@ast
Tim A D Smith
@en
Tim A D Smith
@es
Tim A D Smith
@nl
Tim A D Smith
@sl
prefLabel
Tim A D Smith
@ast
Tim A D Smith
@en
Tim A D Smith
@es
Tim A D Smith
@nl
Tim A D Smith
@sl
P106
P1153
7405500545
P21
P31
P496
0000-0002-3945-630X